246 related articles for article (PubMed ID: 26824303)
1. Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation.
Prijovich ZM; Burnouf PA; Chou HC; Huang PT; Chen KC; Cheng TL; Leu YL; Roffler SR
Mol Pharm; 2016 Apr; 13(4):1242-50. PubMed ID: 26824303
[TBL] [Abstract][Full Text] [Related]
2. Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin.
Prijovich ZM; Leu YL; Roffler SR
Cancer Chemother Pharmacol; 2007 Jun; 60(1):7-17. PubMed ID: 16983566
[TBL] [Abstract][Full Text] [Related]
3. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy.
Leu YL; Chen CS; Wu YJ; Chern JW
J Med Chem; 2008 Mar; 51(6):1740-6. PubMed ID: 18318465
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice.
Prijovich ZM; Chen BM; Leu YL; Chern JW; Roffler SR
Br J Cancer; 2002 May; 86(10):1634-8. PubMed ID: 12085215
[TBL] [Abstract][Full Text] [Related]
5. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
Chen KC; Schmuck K; Tietze LF; Roffler SR
Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).
Leu YL; Roffler SR; Chern JW
J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293
[TBL] [Abstract][Full Text] [Related]
7. Cancer chemotherapy: a SN-38 (7-ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug MonoTherapy) strategy.
Angenault S; Thirot S; Schmidt F; Monneret C; Pfeiffer B; Renard P
Bioorg Med Chem Lett; 2003 Mar; 13(5):947-50. PubMed ID: 12617927
[TBL] [Abstract][Full Text] [Related]
8. Glucuronides in anti-cancer therapy.
Chen X; Wu B; Wang PG
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):139-50. PubMed ID: 12678908
[TBL] [Abstract][Full Text] [Related]
9. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment.
Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR
Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.
Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Jayle C; Alsarraf J; Thomas M; Papot S
Eur J Med Chem; 2013 Sep; 67():75-80. PubMed ID: 23845743
[TBL] [Abstract][Full Text] [Related]
11. A camptothecin-based, albumin-binding prodrug enhances efficacy and safety in vivo.
Cheng Z; Huang Y; Shen Q; Zhao Y; Wang L; Yu J; Lu W
Eur J Med Chem; 2021 Dec; 226():113851. PubMed ID: 34547508
[TBL] [Abstract][Full Text] [Related]
12. Beta-glucuronidase-mediated drug release.
de Graaf M; Boven E; Scheeren HW; Haisma HJ; Pinedo HM
Curr Pharm Des; 2002; 8(15):1391-403. PubMed ID: 12052215
[TBL] [Abstract][Full Text] [Related]
13. Stability of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in the presence of human serum albumin.
Prijovich ZM; Leu YL; Roffler SR
Biochem Pharmacol; 2003 Oct; 66(7):1181-7. PubMed ID: 14505797
[TBL] [Abstract][Full Text] [Related]
14. Curcumin β-D-glucuronide exhibits anti-tumor effects on oxaliplatin-resistant colon cancer with less toxicity in vivo.
Ozawa-Umeta H; Kishimoto A; Imaizumi A; Hashimoto T; Asakura T; Kakeya H; Kanai M
Cancer Sci; 2020 May; 111(5):1785-1793. PubMed ID: 32163218
[TBL] [Abstract][Full Text] [Related]
15. A new cyclopamine glucuronide prodrug with improved kinetics of drug release.
Renoux B; Legigan T; Bensalma S; Chadéneau C; Muller JM; Papot S
Org Biomol Chem; 2011 Dec; 9(24):8459-64. PubMed ID: 22042246
[TBL] [Abstract][Full Text] [Related]
16. A heterodimeric glucuronide prodrug for cancer tritherapy: the double role of the chemical amplifier.
Grinda M; Clarhaut J; Tranoy-Opalinski I; Renoux B; Monvoisin A; Cronier L; Papot S
ChemMedChem; 2011 Dec; 6(12):2137-41. PubMed ID: 21815268
[No Abstract] [Full Text] [Related]
17. Antiangiogenesis targeting tumor microenvironment synergizes glucuronide prodrug antitumor activity.
Juan TY; Roffler SR; Hou HS; Huang SM; Chen KC; Leu YL; Prijovich ZM; Yu CP; Wu CC; Sun GH; Cha TL
Clin Cancer Res; 2009 Jul; 15(14):4600-11. PubMed ID: 19584154
[TBL] [Abstract][Full Text] [Related]
18. Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes.
Chen KC; Cheng TL; Leu YL; Prijovich ZM; Chuang CH; Chen BM; Roffler SR
Cancer Gene Ther; 2007 Feb; 14(2):187-200. PubMed ID: 16977328
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia Targeting Prodrugs.
Liang D; Wu X; Hasinoff BB; Herbert DE; Tranmer GK
Molecules; 2018 Aug; 23(8):. PubMed ID: 30111719
[TBL] [Abstract][Full Text] [Related]
20. A β-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy.
Compain G; Oumata N; Clarhaut J; Péraudeau E; Renoux B; Galons H; Papot S
Eur J Med Chem; 2018 Oct; 158():1-6. PubMed ID: 30199702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
